Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorUniversity Medical Center Groningen
About this trial
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
Eligibility criteria
Qualifiers
Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)
Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).
Prepared for RAI-therapy with TH-withdrawal
Patients must be fit to adhere to the study protocol
Disqualifiers
Pregnancy
Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.
Patients with a history of atrophic gastritis
Patients using proton-pomp inhibitors
Trial design
Treatments tested in this trial
- Euthyrox (levothyroxine)
- Cytomel (liothyronine)
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Medical Center Groningen
Lead sponsor
Radboud University Medical Center
Collaborator
Source ClinicalTrials.gov